BioActor develops clinically evaluated polyphenol extracts from edible plants and fruits.
Ingredients supplier Solabia Group (Paris) has acquired a majority stake in BioActor B.V. (Maastricht, the Netherlands), which develops clinically evaluated polyphenol extracts from edible plants and fruits.
A press release states, “Solabia is already present in the nutrition segment through original ingredients recognized for their health benefits, including Algatech’s microalgae-derived active ingredients. This strategic investment will allow Solabia to benefit from a wider range of ingredients and from BioActor’s expertise, strengthening its nutrition division positioning [in] this fast-growing market as customers increasingly look for high-quality active ingredients that combine naturality with proof of efficacy.”
BioActor will continue to focus on R&D and product development, with the companies stating that “BioActor will become a center of excellence for innovation and clinical research within Solabia’s nutrition division…”